Theseus Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THRX research report →
Companytheseusrx.com
Theseus Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.
- CEO
- Iain D. Dukes DPHIL,
- IPO
- 2021
- Employees
- 38
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $181.50M
- P/E
- -3.32
- P/S
- 0.00
- P/B
- 0.75
- EV/EBITDA
- -1.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.74%
- ROIC
- -23.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-47,080,000 · -72.40%
- EPS
- $-1.22 · -60.53%
- Op Income
- $-54,086,000
- FCF YoY
- -22.88%
Performance & Tape
- 52W High
- $12.37
- 52W Low
- $2.05
- 50D MA
- $3.95
- 200D MA
- $5.00
- Beta
- 3.98
- Avg Volume
- 849.60K
Get TickerSpark's AI analysis on THRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 14, 24 | Yi Kathy | sell | 3,250 |
| Feb 14, 24 | Yi Kathy | sell | 99,634 |
| Feb 14, 24 | Stein Steven H | sell | 3,250 |
| Feb 14, 24 | ORBIMED ADVISORS LLC | other | 650,600 |
| Feb 14, 24 | HAYDEN DONALD J JR | other | 10,000 |
| Feb 14, 24 | HAYDEN DONALD J JR | sell | 3,250 |
| Feb 14, 24 | GORDON CARL L | other | 650,600 |
| Feb 14, 24 | GORDON CARL L | sell | 3,250 |
| Feb 14, 24 | Dukes Iain D. | other | 388,324 |
| Feb 14, 24 | Dukes Iain D. | sell | 61,549 |
Our THRX Coverage
We haven't published any research on THRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THRX Report →